Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease

Archives of Neurology

Volumn 61, Issue 10, 2004, Pages 1613-1615

  Weiner, Howard L ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; GLATIRAMER; INTERLEUKIN 12; MITOXANTRONE; NATALIZUMAB;

ALLERGIC ENCEPHALOMYELITIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; HISTOCOMPATIBILITY; HUMAN; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY CELL; MULTIPLE SCLEROSIS; NONHUMAN; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SHORT SURVEY; T LYMPHOCYTE; TREATMENT OUTCOME;

AUTOIMMUNE DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; MULTIPLE SCLEROSIS; PEPTIDES; T-LYMPHOCYTES;

EID: 5344228374     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.61.10.1613     Document Type: Short Survey

References (15)

1. Sorensen TL, Tani M, Jensen J, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest. 1999;103:807-815.
2. Windhagen A, Newcombe J, Dangond F, et al. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med. 1995;182:1985-1996.
3. Zhang J, Markovic-Plese S, Lacet B, Raus J, Weiner HL, Hafler DA. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med. 1994;179:973-984.
4. Bielekova B, Goodwin B, Richert N, et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med. 2000;6:1167-1175.
5. Yong VW, Chabot S, Stuve O, Williams G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology. 1998;51:682-689.
6. Neuhaus O, Farina C, Wekerle H, Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology. 2001;56:702-708.
7. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003;348:15-23.
8. Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002;360:2018-2025.
9. Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol. 1999;46:296-304.
10. Weiner HL, Cohen JA. Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult Scler. 2002;8:142-154.
11. Makhlouf K, Weiner HL, Khoury SJ. Increased percentage of IL-12+ monocytes in the blood correlates with the presence of active MRI lesions in MS. J Neuroimmunol. 2001;119:145-149.
12. van Boxel-Dezaire AH, Hoff SC, van Oosten BW, et al. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Am Neurol. 1999;45:695-703.
13. Bettelli E, Pagany M, Weiner HL, Linington C, Sobel RA, Kuchroo VK. Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J Exp Med. 2003;197:1073-1081.
14. Pitt D, Werner P, Raine CS. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med. 2000;6:67-70.
15. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000; 47:707-717.